nxp800
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05226507)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06420349 | Phase 1 | May 31, 2024 | Mayo Clinic |
| NCT05226507 | Phase 1 | Dec 31, 2021 | European Network for Gynaecological Oncological Trial, European Network for Gynaecological Oncological Trial Groups, GOG Foundation, Inc., Nuvectis Pharma, Inc., Royal Marsden Hospital NHS Trust |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2021 |
| European Network for Gynaecological Oncological Trial Groups | Academic/Hospital | 1 | 0 | 1 | 2021 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Nuvectis Pharma, Inc. | For profit | 1 | 1 | 1 | 2021 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1